补气汤联合噻托溴铵吸入粉雾剂治疗慢性阻塞性肺疾病稳定期临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R563;R256.1

基金项目:

深圳市医疗卫生三名工程项目(SZZYSM202206014)


Clinical Study on Buqi Decoction Combined with Tiotropium Bromide Powder for Inhalation for Chronic Obstructive Pulmonary Disease at Stable Stage
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察补气汤联合噻托溴铵吸入粉雾剂治疗肺脾气虚型慢性阻塞性肺疾病(COPD) 稳定期临 床疗效。方法:将80例肺脾气虚型COPD稳定期患者按随机数字表法分为对照组和治疗组,每组40例。治疗 组脱落5例,剔除1例,对照组脱落6例,治疗组和对照组各34例完成研究。对照组接受噻托溴铵吸入粉雾剂 治疗,治疗组在对照组基础上加予补气汤治疗,2组均治疗3个月。治疗后,比较2组临床疗效。治疗前后, 比较2组中医证候积分、改良版英国医学研究委员会呼吸困难量表(mMRC) 分级、COPD患者自我评估测 试(CAT) 评分和肺功能。结果:治疗后,治疗组总有效率为94.12%,高于对照组76.47% (P<0.05)。治疗 后,2组中医证候积分、CAT评分均较治疗前降低(P<0.05),治疗组mMRC分级较治疗前降低(P<0.05), 治疗组中医证候积分、CAT 评分和mMRC 分级均低于对照组(P<0.05)。治疗后, 2 组第1 秒用力呼气 量(FEV1)、用力肺活量(FVC) 和FEV1/FVC值均较治疗前升高(P<0.05),治疗组FEV1、FVC和FEV1/FVC 值均高于对照组(P<0.05)。结论:补气汤联合噻托溴铵吸入粉雾剂治疗肺脾气虚型COPD稳定期,能更有效 改善临床症状,提高肺功能,临床疗效显著。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Buqi Decoction combined with Tiotropium Bromide Powder for inhalation on chronic obstructive pulmonary disease (COPD) at stable stage of lungspleen qi deficiency type. Methods:A total of 80 cases of COPD patients at stable stage of lung-spleen qi deficiency type were divided into the control group and the treatment group using a random number table method, with 40 patients in each group. Five cases fell out of the treatment group, with one case excluded;six cases fell out of the control group. In the two groups,there were 34 cases completing the study. The control group received Tiotropium Bromide Powder for inhalation treatment, and the treatment group was treated with Buqi Decoction in addition to the treatment of the control group. Both groups were treated for three months. After treatment,compared the clinical efficacy between the two groups. Before and after treatment, compared the traditional Chinese medicine syndrome scores, dyspnea grading in modified version of the UK Medical Research Council Respiratory Scale (mMRC),COPD Assessment Test (CAT) scores of COPD patients,and lung function between the two groups. Results:After treatment,the total effective rate was 94.12% in the treatment group,which was higher than that of 76.47% in the control group (P<0.05). After treatment, the traditional Chinese medicine syndrome scores, CAT scores in both groups were decreased when compared with those before treatment (P<0.05); the mMRC dyspnea grading in the treatment group was decreased when compared with that before treatment (P<0.05); the traditional Chinese medicine syndrome score, CAT score, and mMRC dyspnea grading in the treatment group were lower than those in the control group (P<0.05). After treatment,the forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC in both groups were increased when compared with those before treatment (P<0.05); the FEV1, FVC, and FEV1/FVC in the treatment group were all higher than those in the control group (P<0.05). Conclusion: Buqi Decoction combined with Tiotropium Bromide Powder for Inhalation for COPD patients at stable stage of lung-spleen qi deficiency type can relieve clinical symptoms more effectively,improve lung function,and achieve significant clinical efficacy.

    参考文献
    相似文献
    引证文献
引用本文

徐铭芝,雷雅涵,谢嘉嘉.补气汤联合噻托溴铵吸入粉雾剂治疗慢性阻塞性肺疾病稳定期临床研究[J].新中医,2024,56(23):40-44

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-12-19
  • 出版日期:
文章二维码